Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.12 -1.4%	$1.55	$1.11 ▼ $5.00	$564.22M	1.76	1.56 million shs	1.89 million shs
BCAX Bicara Therapeutics	$10.84 -6.3%	$12.40	$7.80 ▼ $28.09	$630.98M	N/A	583,377 shs	443,114 shs
EOLS Evolus	$9.93 -2.5%	$10.31	$8.67 ▼ $17.82	$640.25M	1	741,708 shs	1.07 million shs
SLS SELLAS Life Sciences Group	$1.66 +0.6%	$1.53	$0.77 ▼ $2.12	$165.63M	2.25	1.59 million shs	2.61 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	-9.40%	+64.34%	+13.37%	-51.15%
BCAX Bicara Therapeutics	0.00%	-5.74%	-25.09%	-12.72%	+1,083,999,900.00%
EOLS Evolus	0.00%	-1.10%	-0.70%	-24.77%	-13.88%
SLS SELLAS Life Sciences Group	0.00%	+3.11%	+3.75%	+45.61%	+14.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.5585 of 5 stars	3.5	1.0	0.0	2.6	3.3	0.6
BCAX Bicara Therapeutics	2.056 of 5 stars	3.5	0.0	0.0	2.6	0.8	0.6
EOLS Evolus	4.0446 of 5 stars	3.5	1.0	3.5	2.8	3.3	0.6
SLS SELLAS Life Sciences Group	0.506 of 5 stars	0.0	1.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	339.62% Upside
BCAX Bicara Therapeutics	3.00	Buy	$31.86	193.90% Upside
EOLS Evolus	3.00	Buy	$23.75	139.17% Upside
SLS SELLAS Life Sciences Group	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SLS, BCAX, AUTL, and EOLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/17/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight	$8.00
4/17/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/10/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/10/2025	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/9/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/7/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $44.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$9.01M	62.61	N/A	N/A	$0.64 per share	3.31
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	$275.46M	2.32	N/A	N/A	($0.36) per share	-27.58
SLS SELLAS Life Sciences Group	$1M	165.63	N/A	N/A	($0.25) per share	-6.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$208.38M	-$0.88	N/A	N/A	N/A	N/A	-63.65%	-36.54%	8/14/2025 (Estimated)
BCAX Bicara Therapeutics	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/26/2025 (Estimated)
EOLS Evolus	-$61.69M	-$0.89	N/A	N/A	N/A	-22.33%	-847.60%	-22.15%	7/30/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$37.34M	-$0.38	N/A	N/A	N/A	N/A	-629.46%	-178.65%	8/12/2025 (Estimated)

Latest SLS, BCAX, AUTL, and EOLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
3/27/2025	Q4 2024	BCAX Bicara Therapeutics	-$0.31	-$0.39	-$0.08	-$0.39	N/A	N/A
3/20/2025	Q4 2024	AUTL Autolus Therapeutics	-$0.21	-$0.09	+$0.12	-$0.09	$2.98 million	$0.03 million
3/20/2025	Q4 2024	SLS SELLAS Life Sciences Group	-$0.1067	-$0.08	+$0.0267	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	13.69	13.69
BCAX Bicara Therapeutics	N/A	N/A	N/A
EOLS Evolus	20.58	2.47	2.23
SLS SELLAS Life Sciences Group	N/A	2.26	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
BCAX Bicara Therapeutics	N/A
EOLS Evolus	90.69%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
BCAX Bicara Therapeutics	15.50%
EOLS Evolus	5.90%
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.71 million	Optionable
BCAX Bicara Therapeutics	32	54.54 million	N/A	N/A
EOLS Evolus	170	64.48 million	59.46 million	Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	69.54 million	Not Optionable

SLS, BCAX, AUTL, and EOLS Headlines

Recent News About These Companies

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14 at 8:41 AM | insidertrades.com

Nostrand Robert L. Van Acquires 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 13 at 11:55 AM | marketbeat.com

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

June 5, 2025 | globenewswire.com

SELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025

June 4, 2025 | nasdaq.com

Insider Buying: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Purchases 20,000 Shares of Stock

June 3, 2025 | marketbeat.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 Shares

June 3, 2025 | insidertrades.com

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

594,919 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Bought by Brooklyn FI LLC

May 28, 2025 | marketbeat.com

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock

May 16, 2025 | fxempire.com

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

May 16, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | finanznachrichten.de

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | globenewswire.com

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025

April 28, 2025 | quiverquant.com

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

April 28, 2025 | globenewswire.com

Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 8.95%

April 26, 2025 | aaii.com

SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting

April 23, 2025 | quiverquant.com

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025 | globenewswire.com

Sellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trial

April 9, 2025 | markets.businessinsider.com

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

April 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS, BCAX, AUTL, and EOLS Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.12 -0.03 (-1.40%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.12 +0.00 (+0.24%)

As of 06/13/2025 07:46 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Bicara Therapeutics NASDAQ:BCAX

$10.84 -0.73 (-6.31%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$10.90 +0.06 (+0.60%)

As of 06/13/2025 07:00 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Evolus NASDAQ:EOLS

$9.93 -0.25 (-2.46%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$9.94 +0.02 (+0.15%)

As of 06/13/2025 05:50 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

SELLAS Life Sciences Group NASDAQ:SLS

$1.66 +0.01 (+0.61%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.06 (+3.31%)

As of 06/13/2025 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time